The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

AACR 2017 | Poster 4192/15 – targeting SHP-1/p-Lyn signaling shows therapeutic potential in Diffuse Large B-Cell Lymphoma

Apr 11, 2017

At the American Association for Cancer Research(AACR) annual meeting in Washington, DC, USA, on Tuesday 4 thApril, a poster session titled “ Targeting Protein Kinases and DNA Repair” took place.

One of the posters on display ( 4192 / 15) was titled “Targeting SHP-1/p-Lyn signaling shows therapeutic potential in diffuse large B-cell lymphoma” by Chun-Yu Liufrom Taipei Veterans General Hospital, Taipei, Taiwan, and colleagues.

The group aimed to investigate the biological role and potential therapeutic implication of SHP-1, a protein phosphatase, in DLBCL. In vitrostudies used ABC-like cell lines U2932 and Ly-3, as well as GC-like cell lines DHL-6, Ly-7, and DB. Nude mice with DLBCL xenografts were used for in vivotherapeutic testing of AHP-1 agonists.

Key Highlights:

  • Ln general, SHP-1/p-STAT3 expression was higher in ABC-like cells
  • Expression of p-Lyn (Tyr396) and p-BTK (Tyr223), key components of the BCR signaling pathway, were higher in ABC-like cells
  • Knockdown or overexpression of SHP-1 expression caused a reciprocal change of p-Lyn; indicates SHP-1 negatively regulates Lyn kinase phosphorylation
  • Immunoprecipitation experiments confirmed SHP-1 interacts with Lyn in DLBCL cells
  • Then tested SHP-1 agonists (SC-43 and SC-60) versusibrutinib
  • In general, SHP-1 agonists showed superior anti-proliferative and apoptotic effects vsibrutinib
  • Mechanistically, SHP-1 agonists enhanced SHP-1 activity, decreased BCR signaling by p-Lyn and p-BTK, which led to apoptosis
  • SHP-1 agonists found to down-regulate p-STAT3, also contributing anti-cancer effects
  • In mice bearing U2932 xenografts, SC-43 administered orally at 10mg/kg/day and 30mg/kg/day demonstrated similar anti-tumor effects as ibrutinib at doses of 12.5mg/kg/day and 25mg/kg/day, respectively
  • Western blot confirmed SC-43 mediated down-regulation of p-Lyn and p-BTK in vivo

The poster was concluded by stating that phosphorylation of Lyn is negatively regulated by SHP-1. Using SHP-1 agonists to target SHP-1/p-Lyn demonstrated therapeutic potential in DLBCL in vivoand in vitromodels.

  1. Liu C.Y. et al.Targeting SHP-1/p-Lyn signaling shows therapeutic potential in diffuse large B-cell lymphoma [Poster]. In: Proceedings of the 107th Annual Meetingof the American Association for Cancer Research; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; 2017. Poster nr [ 4192 / 15].